Generic placeholder image

Current Cancer Therapy Reviews

Author(s): Deepa Mandal and Tithi Parija*

DOI: 10.2174/1573394718666220421112750

DownloadDownload PDF Flyer Cite As
Anticancer Mechanism of D-limonene: An Updated Review and Therapeutic Possibilities

Page: [193 - 201] Pages: 9

  • * (Excluding Mailing and Handling)

Abstract

Background: Despite remarkable advancement in screening, diagnosis, and treatment modalities, cancer remains the second leading cause of death globally. Chemoprevention is considered to be a potential strategy for dealing with cancer incidence and mortality. The present demand for a less toxic well-tolerated natural anticancer compound that can be used for chemoprevention has drawn the attention towards D-limonene, which is a monocyclic monoterpene found in citrus oil. In recent years several in vitro and in vivo studies have supported the anticancer potential of D-limonene in various cancers. Although these studies have highlighted its course of action through immune modulation, anti-oxidant activity, apoptosis, autophagy, etc. various scientific pieces of evidence support the fact that it targets multiple pathways to inhibit cancer.

Objective: The current review focuses on the molecular mechanisms underlying the anticancer activity of D-limonene and discusses its potential as a cost-effective chemopreventive and chemotherapeutic drug alone or in combination with other drugs.

Methods: Scientific databases like Web of Science, Scopus, PubMed, Google Scholar, PubMed Central, etc. have been used to review new insights into the anticancer mechanism of D-limonene.

Conclusion: In this review, we discussed the overall significance of the anticancer mechanisms of D-limonene which include modulation of apoptosis, promotion of autophagy and inhibition of angiogenesis and metastasis. D-limonene also inhibits oncogenic signaling molecules and related transcription factors. Additionally, it also acts in combination with other anticancer compounds to inhibit cancer.

Keywords: D-limonene, cancer, chemoprevention, apoptosis, angiogenesis, autophagy.

Graphical Abstract

[1]
Steward WP, Brown K. Cancer chemoprevention: A rapidly evolving field. Br J Cancer 2013; 109(1): 1-7.
[http://dx.doi.org/10.1038/bjc.2013.280] [PMID: 23736035]
[2]
Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis 2000; 21(3): 525-30.
[http://dx.doi.org/10.1093/carcin/21.3.525] [PMID: 10688873]
[3]
Benetou V, Lagiou A, Lagiou P. Chemoprevention of cancer: Current evidence and future prospects. F1000 Res 2015; 4: 916.
[4]
Cazzaniga M, Bonanni B. Breast cancer chemoprevention: Old and new approaches. J Biomed Biotechnol 2012; 2012: 985620.
[http://dx.doi.org/10.1155/2012/985620] [PMID: 22851887]
[5]
Pratheeshkumar P, Sreekala C, Zhang Z, et al. Cancer prevention with promising natural products: Mechanisms of action and molecular targets. Anticancer Agents Med Chem 2012; 12(10): 1159-84.
[http://dx.doi.org/10.2174/187152012803833035] [PMID: 22583402]
[6]
Sun J. D-Limonene: Safety and clinical applications. Altern Med Rev 2007; 12(3): 259-64.
[PMID: 18072821]
[7]
Miller JA, Hakim IA, Chew W, Thompson P, Thomson CA, Chow HH. Adipose tissue accumulation of d-limonene with the consumption of a lemonade preparation rich in d-limonene content. Nutr Cancer 2010; 62(6): 783-8.
[http://dx.doi.org/10.1080/01635581003693066] [PMID: 20661827]
[8]
Chen C, Sheng Y, Hu Y, et al. Determination of d-limonene in mice plasma and tissues by a new GC-MS/MS method: Comparison of the pharmacokinetics and tissue distribution by oral and inhalation administration in mice. Biomed Chromatogr 2019; 33(7): e4530.
[http://dx.doi.org/10.1002/bmc.4530] [PMID: 30845345]
[9]
Ramos CAF, Sá RCDS, Alves MF, et al. Histopathological and biochemical assessment of d-limonene-induced liver injury in rats. Toxicol Rep 2015; 2: 482-8.
[http://dx.doi.org/10.1016/j.toxrep.2015.01.001] [PMID: 28962384]
[10]
Crowell PL. Prevention and therapy of cancer by dietary monoterpenes. J Nutr 1999; 129(3): 775S-8S.
[http://dx.doi.org/10.1093/jn/129.3.775S] [PMID: 10082788]
[11]
Vieira AJ, Beserra FP, Souza MC, Totti BM, Rozza AL. Limonene: Aroma of innovation in health and disease. Chem Biol Interact 2018; 283: 97-106.
[http://dx.doi.org/10.1016/j.cbi.2018.02.007] [PMID: 29427589]
[12]
Miller JA, Thompson PA, Hakim IA, Chow HHS, Thomson CA. D-Limonene: A bioactive food component from citrus and evidence for a potential role in breast cancer prevention and treatment. Oncol Rev 2011; 5(1): 31-42.
[http://dx.doi.org/10.1007/s12156-010-0066-8]
[13]
Crowell PL, Gould MN. Chemoprevention and therapy of cancer by d-limonene. Crit Rev Oncog 1994; 5(1): 1-22.
[http://dx.doi.org/10.1615/CritRevOncog.v5.i1.10] [PMID: 7948106]
[14]
Rabi T, Gupta S. Dietary terpenoids and prostate cancer chemoprevention. Front Biosci 2008; 13(13): 3457-69.
[http://dx.doi.org/10.2741/2940] [PMID: 18508447]
[15]
Sobral M, Xavier AL, Lima TC, de Sousa DP. Antitumor activity of monoterpenes found in essential oils. Sci World J 2014; 953451.
[http://dx.doi.org/10.1155/2014/953451]
[16]
Wagner JE, Huff JL, Rust WL, Kingsley K, Plopper GE. Perillyl alcohol inhibits breast cell migration without affecting cell adhesion. J Biomed Biotechnol 2002; 2(3): 136-40.
[http://dx.doi.org/10.1155/S1110724302207020] [PMID: 12488578]
[17]
Mauro M, Catanzaro I, Naselli F, Sciandrello G, Caradonna F. Abnormal mitotic spindle assembly and cytokinesis induced by D-Limonene in cultured mammalian cells. Mutagenesis 2013; 28(6): 631-5.
[http://dx.doi.org/10.1093/mutage/get040] [PMID: 23913329]
[18]
Crowell PL, Chang RR, Ren ZB, Elson CE, Gould MN. Selective inhibition of isoprenylation of 21-26-kDa proteins by the anticarcinogen d-limonene and its metabolites. J Biol Chem 1991; 266(26): 17679-85.
[http://dx.doi.org/10.1016/S0021-9258(19)47425-5] [PMID: 1894647]
[19]
Jirtle RL, Haag JD, Ariazi EA, Gould MN. Increased mannose 6-phosphate/insulin-like growth factor II receptor and transforming growth factor β 1 levels during monoterpene-induced regression of mammary tumors. Cancer Res 1993; 53(17): 3849-52.
[PMID: 8358708]
[20]
Sarkar S, Quinn BA, Shen X, et al. Reversing translational suppression and induction of toxicity in pancreatic cancer cells using a chemo-prevention gene therapy approach. Mol Pharmacol 2015; 87(2): 286-95.
[http://dx.doi.org/10.1124/mol.114.094375] [PMID: 25452327]
[21]
Hakim IA, Harris RB, Ritenbaugh C. Citrus peel use is associated with reduced risk of squamous cell carcinoma of the skin. Nutr Cancer 2000; 37(2): 161-8.
[http://dx.doi.org/10.1207/S15327914NC372_7] [PMID: 11142088]
[22]
Hafidh RR, Hussein SZ. MalAllah MQ, Abdulamir AS, Abu Bakar F. A high-throughput quantitative expression analysis of cancer-related genes in human HepG2 cells in response to limonene, a potential anticancer agent. Curr Cancer Drug Targets 2018; 18(8): 807-15.
[http://dx.doi.org/10.2174/1568009617666171114144236] [PMID: 29141549]
[23]
Feng T, Zhang Q, Li Q, et al. LUAD transcriptomic profile analysis of d-limonene and potential lncRNA chemopreventive target. Food Funct 2020; 11(8): 7255-65.
[http://dx.doi.org/10.1039/D0FO00809E] [PMID: 32776051]
[24]
Parija T, Das BR. Involvement of YY1 and its correlation with c-myc in NDEA induced hepatocarcinogenesis, its prevention by d-limonene. Mol Biol Rep 2003; 30(1): 41-6.
[http://dx.doi.org/10.1023/A:1022207630482] [PMID: 12688534]
[25]
Yu X, Lin H, Wang Y, et al. d-limonene exhibits antitumor activity by inducing autophagy and apoptosis in lung cancer. OncoTargets Ther 2018; 11: 1833-47.
[http://dx.doi.org/10.2147/OTT.S155716] [PMID: 29670359]
[26]
Araújo-Filho HGD, Dos Santos JF, Carvalho MTB, et al. Anticancer activity of limonene: A systematic review of target signaling path-ways. Phytother Res 2021; 35(9): 4957-4970, 7125.
[http://dx.doi.org/10.1002/ptr.7125] [PMID: 33864293]
[27]
Md Othman S, Hassan M, Nahar L, Basar N, Jamil S, Sarker S. Essential oils from the Malaysian Citrus (Rutaceae) medicinal plants. Medicines (Basel) 2016; 3(2): 13.
[http://dx.doi.org/10.3390/medicines3020013]
[28]
Bozkurt T, Gulnaz O, Kacar YA. Chemical composition of the essential oils from some citrus species and evaluation of the antimicrobial activity. IOSR-JESTFT 2017; 11: 2319-99.
[29]
Viuda-Martos M, Ruiz-Navajas Y, Fernandez-Lopez J, Perez-Alvarez JA. Chemical composition of mandarin (C. reticulata L.), grapefruit (C. paradisi L.), lemon (C. limon L.), and orange (C. sinensis L.) essential oils. J Essent Oil-Bear Plants 2009; 12(2): 236-43.
[http://dx.doi.org/10.1080/0972060X.2009.10643716]
[30]
Evbuomwan BO, Fashola RA, Dakor A. Insecticidal potential of grapefruit and tangerine peel essential oils extracted by steam distillation. J Sci Engin Res 2016; 3: 181-7.
[31]
Rana VS, Blazquez MA. Compositions of the volatile oils of Citrus macroptera and C. maxima. Nat Prod Commun 2012; 7(10): 1371-2.
[http://dx.doi.org/10.1177/1934578X1200701032] [PMID: 23157014]
[32]
Boughendjioua H, Boughendjioua Z. Chemical composition and biological activity of essential oil of mandarin (Citrus reticulata) cultivated in Algeria. Int J Pharm Sci Rev Res 2017; 44: 179-84.
[33]
Njoku V, Evbuomwan B. Analysis and comparative study of essential oil extracted from Nigerian orange, lemon and lime peels. Greener J Chem Sci Tech 2014; 1(1): 6-14.
[http://dx.doi.org/10.15580/GJCST.2014.1.041414185]
[34]
Hah SA, Ea O. Essential oil content and chemical composition of eight dill (Anethum graveolens L) cultivars cultivated under Egyptian conditions. Int J Pharm Pharm Sci 2016; 1: 227-31.
[35]
Rombolà L, Tridico L, Scuteri D, et al. Bergamot essential oil attenuates anxiety-like behaviour in rats. Molecules 2017; 22(4): 614.
[http://dx.doi.org/10.3390/molecules22040614] [PMID: 28398260]
[36]
Elmore S. Apoptosis: A review of programmed cell death. Toxicol Pathol 2007; 35(4): 495-516.
[http://dx.doi.org/10.1080/01926230701320337] [PMID: 17562483]
[37]
Parrish AB, Freel CD, Kornbluth S. Cellular mechanisms controlling caspase activation and function. Cold Spring Harb Perspect Biol 2013; 5(6): a008672.
[http://dx.doi.org/10.1101/cshperspect.a008672] [PMID: 23732469]
[38]
Cavalcante GC, Schaan AP, Cabral GF, et al. A cell’s fate: An overview of the molecular biology and genetics of apoptosis. Int J Mol Sci 2019; 20(17): 4133-53.
[http://dx.doi.org/10.3390/ijms20174133] [PMID: 31450613]
[39]
Pourahmad J, Salimi A, Seydi E. Natural compounds target mitochondrial alterations in cancer cell: New avenue for anticancer research. Iran J Pharm Res 2014; 13 (Suppl.): 1-2.
[PMID: 24711823]
[40]
Cerqueira Braz JDV, de Carvalho FO, Cerqueira Meneses DDV, et al. Mechanism of action of limonene in tumor cells: A systematic re-view and metanalysis. Curr Pharm Des 2021; 27: 1-10.
[41]
Jia SS, Xi GP, Zhang M, et al. Induction of apoptosis by D-limonene is mediated by inactivation of Akt in LS174T human colon cancer cells. Oncol Rep 2013; 29(1): 349-54.
[http://dx.doi.org/10.3892/or.2012.2093] [PMID: 23117412]
[42]
Firoozinia M, Moghadamtousi SZ, Sadeghilar A, Karimian H, Noordin MIB. Golden natural plant compounds activate apoptosis via both mitochondrial and death receptor pathways: A Review. E J Bio 2015; 11: 126-37.
[43]
Gupta S, Kass GE, Szegezdi E, Joseph B. The mitochondrial death pathway: A promising therapeutic target in diseases. J Cell Mol Med 2009; 13(6): 1004-33.
[http://dx.doi.org/10.1111/j.1582-4934.2009.00697.x] [PMID: 19220575]
[44]
Suarez-Jimenez GM, Burgos-Hernandez A, Ezquerra-Brauer JM. Bioactive peptides and depsipeptides with anticancer potential: Sources from marine animals. Mar Drugs 2012; 10(5): 963-86.
[http://dx.doi.org/10.3390/md10050963] [PMID: 22822350]
[45]
Yu Z, Wang W, Xu L, Dong J, Jing Y. d-Limonene and d-carvone induce apoptosis in HL-60 cells through activation of caspase-8. Asian J Tradit Med 2008; 3: 134-43.
[46]
Manuele MG, Barreiro Arcos ML, Davicino R, Ferraro G, Cremaschi G, Anesini C. Limonene exerts antiproliferative effects and increases nitric oxide levels on a lymphoma cell line by dual mechanism of the ERK pathway: Relationship with oxidative stress. Cancer Invest 2010; 28(2): 135-45.
[http://dx.doi.org/10.3109/07357900903179583] [PMID: 19968502]
[47]
Ye Z, Liang Z, Mi Q, Guo Y. Limonene terpenoid obstructs human bladder cancer cell (T24 cell line) growth by inducing cellular apopto-sis, caspase activation, G2/M phase cell cycle arrest and stops cancer metastasis. J BUON 2020; 25(1): 280-5.
[PMID: 32277643]
[48]
Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132(1): 27-42.
[http://dx.doi.org/10.1016/j.cell.2007.12.018] [PMID: 18191218]
[49]
Chen N, Debnath J. Autophagy and tumorigenesis. FEBS Lett 2010; 584(7): 1427-35.
[http://dx.doi.org/10.1016/j.febslet.2009.12.034] [PMID: 20035753]
[50]
Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer 2017; 17(9): 528-42.
[http://dx.doi.org/10.1038/nrc.2017.53] [PMID: 28751651]
[51]
Hsieh LC, Hsieh SL, Chen CT, Chung JG, Wang JJ, Wu CC. Induction of α-phellandrene on autophagy in human liver tumor cells. Am J Chin Med 2015; 43(1): 121-36.
[http://dx.doi.org/10.1142/S0192415X15500081] [PMID: 25649747]
[52]
Kim SH, Park EJ, Lee CR, et al. Geraniol induces cooperative interaction of apoptosis and autophagy to elicit cell death in PC-3 prostate cancer cells. Int J Oncol 2012; 40(5): 1683-90.
[PMID: 22200837]
[53]
Russo R, Cassiano MGV, Ciociaro A, et al. Role of D-Limonene in autophagy induced by bergamot essential oil in SH-SY5Y neuroblas-toma cells. PLoS One 2014; 9(11): e113682.
[http://dx.doi.org/10.1371/journal.pone.0113682] [PMID: 25419658]
[54]
Berliocchi L, Chiappini C, Adornetto A, et al. Early LC3 lipidation induced by d-limonene does not rely on mTOR inhibition, ERK activa-tion and ROS production and it is associated with reduced clonogenic capacity of SH-SY5Y neuroblastoma cells. Phytomedicine 2018; 40: 98-105.
[http://dx.doi.org/10.1016/j.phymed.2018.01.005] [PMID: 29496180]
[55]
Gentile D, Berliocchi L, Russo R, Bagetta G, Corasaniti MT. Effects of the autophagy modulators d-limonene and chloroquine on vimentin levels in SH-SY5Y cells. Biochem Biophys Res Commun 2020; 533(4): 764-9.
[http://dx.doi.org/10.1016/j.bbrc.2020.09.073] [PMID: 32988589]
[56]
Pollina EA, Legesse-Miller A, Haley EM, Goodpaster T, Randolph-Habecker J, Coller HA. Regulating the angiogenic balance in tissues. Cell Cycle 2008; 7(13): 2056-70.
[http://dx.doi.org/10.4161/cc.7.13.6240] [PMID: 18642446]
[57]
Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vasc Health Risk Manag 2006; 2(3): 213-9.
[http://dx.doi.org/10.2147/vhrm.2006.2.3.213] [PMID: 17326328]
[58]
Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer 2013; 13(12): 871-82.
[http://dx.doi.org/10.1038/nrc3627] [PMID: 24263190]
[59]
Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005; 69 (Suppl. 3): 11-6.
[http://dx.doi.org/10.1159/000088479] [PMID: 16301831]
[60]
Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69 (Suppl. 3): 4-10.
[http://dx.doi.org/10.1159/000088478] [PMID: 16301830]
[61]
Costa MF, Durço AO, Rabelo TK, Barreto RSS, Guimarães AG. Effects of carvacrol, thymol and essential oils containing such monoter-penes on wound healing: A systematic review. J Pharm Pharmacol 2019; 71(2): 141-55.
[http://dx.doi.org/10.1111/jphp.13054] [PMID: 30537169]
[62]
Kim MS, Lee YM, Moon EJ, Kim SE, Lee JJ, Kim KW. Anti-angiogenic activity of torilin, a sesquiterpene compound isolated from Torilis japonica. Int J Cancer 2000; 87(2): 269-75.
[http://dx.doi.org/10.1002/1097-0215(20000715)87:2<269::AID-IJC19>3.0.CO;2-W] [PMID: 10861486]
[63]
Loutrari H, Hatziapostolou M, Skouridou V, et al. Perillyl alcohol is an angiogenesis inhibitor. J Pharmacol Exp Ther 2004; 311(2): 568-75.
[http://dx.doi.org/10.1124/jpet.104.070516] [PMID: 15210838]
[64]
d’Alessio PA, Mirshahi M, Bisson JF, Bene MC. Skin repair properties of d-Limonene and perillyl alcohol in murine models. Antiinflamm Antiallergy Agents Med Chem 2014; 13(1): 29-35.
[http://dx.doi.org/10.2174/18715230113126660021] [PMID: 24160248]
[65]
Shah BB, Baksi R, Chaudagar KK, Nivsarkar M, Mehta AA. Anti-leukemic and anti-angiogenic effects of d-Limonene on K562-implanted C57BL/6 mice and the chick chorioallantoic membrane model. Animal Model Exp Med 2018; 1(4): 328-33.
[http://dx.doi.org/10.1002/ame2.12039] [PMID: 30891583]
[66]
Sodhi A, Montaner S, Miyazaki H, Gutkind JS. MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1α in rasV12 upregulation of VEGF. Biochem Biophys Res Commun 2001; 287(1): 292-300.
[http://dx.doi.org/10.1006/bbrc.2001.5532] [PMID: 11549290]
[67]
Chidambara Murthy KN, Jayaprakasha GK, Patil BS. D-limonene rich volatile oil from blood oranges inhibits angiogenesis, metastasis and cell death in human colon cancer cells. Life Sci 2012; 91(11-12): 429-39.
[http://dx.doi.org/10.1016/j.lfs.2012.08.016] [PMID: 22935404]
[68]
Lu XG, Zhan LB, Feng BA, Qu MY, Yu LH, Xie JH. Inhibition of growth and metastasis of human gastric cancer implanted in nude mice by d-limonene. World J Gastroenterol 2004; 10(14): 2140-4.
[http://dx.doi.org/10.3748/wjg.v10.i14.2140] [PMID: 15237454]
[69]
Rabi T, Bishayee A. d -Limonene sensitizes docetaxel-induced cytotoxicity in human prostate cancer cells: Generation of reactive oxygen species and induction of apoptosis. J Carcinog 2009; 8(1): 9.
[http://dx.doi.org/10.4103/1477-3163.51368] [PMID: 19465777]
[70]
Chander SK, Lansdown AGB, Luqmani YA, et al. Effectiveness of combined limonene and 4-hydroxyandrostenedione in the treatment of NMU-induced rat mammary tumours. Br J Cancer 1994; 69(5): 879-82.
[http://dx.doi.org/10.1038/bjc.1994.170] [PMID: 8180018]
[71]
Zhang XZ, Wang L, Liu DW, Tang GY, Zhang HY. Synergistic inhibitory effect of berberine and d-limonene on human gastric carcinoma cell line MGC803. J Med Food 2014; 17(9): 955-62.
[http://dx.doi.org/10.1089/jmf.2013.2967] [PMID: 25045784]
[72]
Reddy RRY. Sekhar, C.P. Limonene and BEZ 235 inhibits growth of COLO-320 and HCT-116 colon cancer cells. Int J Drug Deliv 2016; 8(3): 89-95.
[http://dx.doi.org/10.5138/09750215.1919]
[73]
Kawata S, Nagase T, Yamasaki E, Ishiguro H, Matsuzawa Y. Modulation of the mevalonate pathway and cell growth by pravastatin and d-limonene in a human hepatoma cell line (Hep G2). Br J Cancer 1994; 69(6): 1015-20.
[http://dx.doi.org/10.1038/bjc.1994.199] [PMID: 8198962]
[74]
Vigushin DM, Poon GK, Boddy A, et al. Cancer Research Campaign Phase I/II Clinical Trials Committee. Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Chemother Pharmacol 1998; 42(2): 111-7.
[http://dx.doi.org/10.1007/s002800050793] [PMID: 9654110]
[75]
Miller JA, Lang JE, Ley M, et al. Human breast tissue disposition and bioactivity of limonene in women with early-stage breast cancer. Cancer Prev Res (Phila) 2013; 6(6): 577-84.
[http://dx.doi.org/10.1158/1940-6207.CAPR-12-0452] [PMID: 23554130]
[76]
Miller JA, Pappan K, Thompson PA, et al. Plasma metabolomic profiles of breast cancer patients after short-term limonene intervention. Cancer Prev Res (Phila) 2015; 8(1): 86-93.
[http://dx.doi.org/10.1158/1940-6207.CAPR-14-0100] [PMID: 25388013]
[77]
Kim YW, Kim MJ, Chung BY, et al. Safety evaluation and risk assessment of d-Limonene. J Toxicol Environ Health B Crit Rev 2013; 16(1): 17-38.
[http://dx.doi.org/10.1080/10937404.2013.769418] [PMID: 23573938]
[78]
Giri RK, Parija T, Das BR. d-limonene chemoprevention of hepatocarcinogenesis in AKR mice: Inhibition of c-jun and c-myc. Oncol Rep 1999; 6(5): 1123-7.
[http://dx.doi.org/10.3892/or.6.5.1123] [PMID: 10425313]
[79]
Chaudhary SC, Siddiqui MS, Athar M, Alam MS. D-Limonene modulates inflammation, oxidative stress and Ras-ERK pathway to inhibit murine skin tumorigenesis. Hum Exp Toxicol 2012; 31(8): 798-811.
[http://dx.doi.org/10.1177/0960327111434948] [PMID: 22318307]